Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | LCAT | P04180 | 1/20 | 0.37 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15205622 | 0.92 | HRH3 (0.41) | AKR1C3HRH3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL1751229 | 0.92 | HRH3 (0.41) | AKR1C3HRH3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL1751227 | 0.92 | HRH3 (0.41) | AKR1C3HRH3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL13547454 | 0.86 | ACACB (0.45) | AKR1C3HRH3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL9537580 | 0.86 | AKR1C3 (0.46) | AKR1C3HRH3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL15205573 | 0.85 | ACACB (0.39) | AKR1C3HRH3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL15206013 | 0.85 | ACACB (0.39) | AKR1C3HRH3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL2144127 | 0.84 | HRH3 (0.40) | HRH3GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL15205613 | 0.82 | AOC3 (0.34) | PANK3ACACBCXCR3 | |
| SCHEMBL15205553 | 0.81 | PDE10A (0.43) | AKR1C3GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2634176-A1 | PYRIDINE DERIVATIVE AND MEDICINAL AGENT | Nippon Shinyaku Co., Ltd. (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-20130225548-A1 | Pyridine Derivative and Medicinal Agent | NIPPON SHINYAKU CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20100004245-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-01-07 | — | — | US | disclosed |
| EP-2076509-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008046226-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225548-A1 | Pyridine Derivative and Medicinal Agent | NR0B2, NR0B1, CNKSR1 | AKR1C3 150/4885HRH3 49/4885GRIN2D 1321/4885 |
| US-20100004245-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | AKR1C3 807/4885HRH3 4665/4885GRIN2D 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.